Patent intelligence · US
US 11931328
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Patent details — US 11931328
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 19, 2024
- Expiration
- Mar 14, 2044
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Claims
- 18
- CPC classes
- A61K, A61K31/197, A61K9/0095, A61K9/1611
Quick answer
US 11931328 (Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives) is held by AMNEAL PHARMACEUTICALS LLC. Status: granted. Granted Mar 19, 2024. Expires Mar 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/197, A61K9/0095, A61K9/1611, A61K9/1617, A61K9/1623
More from AMNEAL PHARMACEUTICALS LLC
Related pharmaceutical patents in our USPTO index.
-
US 12383522
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted -
US 12370163
Levodopa dosing regimen
granted -
US 12303482
Levodopa dosing regimen
granted -
US 12303481
Levodopa dosing regimen
granted -
US 12295931
Levodopa dosing regimen
granted -
US 12263149
Levodopa dosing regimen
granted -
US 12263148
Levodopa dosing regimen
granted -
US 12233166
Extended release compositions comprising pyridostigmine
granted
Frequently asked questions
What is US patent 11931328?
US 11931328 (Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives) is held by AMNEAL PHARMACEUTICALS LLC. Status: granted. Granted Mar 19, 2024. Expires Mar 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11931328?
AMNEAL PHARMACEUTICALS LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.
When does US 11931328 expire?
Our index shows an expiration date of Mar 14, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.